皮肤毒性测试市场－全球产业规模、份额、趋势、机会与预测：测试类型、测试方法类型、最终用户、地区和竞争格局，2021-2031年

全球皮肤毒性​​测试市场预计将从 2025 年的 21.1 亿美元成长到 2031 年的 33.8 亿美元，复合年增长率为 8.17%。

这个测试领域对于评估潜在的皮肤损伤（例如刺激和腐蚀）以及局部接触引起的全身性影响至关重要，是製药、化学和化妆品行业安全合规的基础。该市场的成长主要得益于严格的监管要求（例如 REACH 法规）以及日益增长的伦理努力，即以体外（试管内）和电脑模拟等替代方法取代动物试验。例如，欧洲化学工业理事会 (Cefic) 报告称，到 2024 年，欧洲化学工业的销售额将达到 6,350 亿欧元，这足以说明需要评估的物质规模之大。

儘管存在这些成长要素，但市场在监管协调和替代调查方法的科学检验方面仍面临许多重大障碍。虽然非动物模型已取得进展，但要证明其与复杂的生物系统完全等效仍然是一项重大挑战。这项挑战可能会阻碍这些调查方法的普遍接受，并限制市场的进一步扩张，因为证明其与传统模型具有可比性仍然是一个重大障碍。

市场驱动因素

全球化妆品和个人护理行业的强劲增长，得益于复杂配方和新成分的不断涌现，而这些都需要进行全面的安全评估，这也成为皮肤毒性测试市场的主要驱动力。随着消费者对产品安全性的关注度日益提高，製造商必须进行广泛的皮肤相容性评估，以确保符合国际标准并预防不良反应。这种高强度的产品开发週期催生了对毒性评估的巨大需求，以确保产品已做好上市准备。欧洲化妆品协会（Cosmetics Europe）发布的《2024年年度报告》显示，预计到2024年，欧洲化妆品和个人保健部门的零售额将达到1040亿欧元，这充分体现了这一需求的规模。

同时，受伦理考量和监管变革（例如FDA现代化法案2.0）的推动，市场正经历变革，非动物实验替代方法正被迅速采用。这一转变加速了3D重建人类表皮模型的商业化进程，与动物实验相比，这些模型在预测人类皮肤反应方面具有更高的准确性。赛多利斯公司于2025年4月达成协议，以8,000万美元收购3D组织模型领域的领导企业MatTek，凸显了这些创新技术的战略重要性。此外，对专业外部专家的依赖也为合约研究领域提供了支持，查尔斯河实验室2025年11月公布的「药物发现与安全性评估」业务收入达6.007亿美元便印证了这一点。

市场挑战

全球皮肤毒性​​测试市场面临的主要障碍之一是替代测试方法的科学检验和监管协调过程的复杂性。要证明非动物模型（例如In Silico和体外技术）能够完全模拟完整生物系统的复杂生理反应，在科学上极具挑战性，这往往导致监管机构在核准这些新方法时犹豫不决。这种谨慎态度造成了法规环境的碎片化，特定测试方法的核准情况于特定地区，这给面临各种合规标准的服务提供者和客户带来了极大的不确定性。

因此，缺乏统一标准减缓了先进替代技术的商业性化应用，并限制了市场的获利潜力。製造商面临更高的合规成本和产品上市延迟，这实际上阻碍了该行业逐步淘汰传统动物试验的计划。其经济影响巨大。根据欧洲化妆品协会（Cosmetics Europe）的报告显示，预计到2024年，欧洲化妆品和个人护理市场的零售额将达到1040亿欧元，但由于缺乏普遍认可的、简化的检验通讯协定来评估如此庞大的产品量，直接阻碍了市场的营运效率和成长轨迹。

市场趋势

将人工智慧 (AI) 应用于预测毒理学正在改变市场格局，使安全性评估从被动的动物试验观察转向数据驱动的预测方法。这一趋势利用机器学习演算法快速分析庞大的化合物库并预测毒性终点，从而鼓励製药公司利用这些平台来降低早期资产的风险。 Exscientia 的案例凸显了计算毒理学的商业性可行性。该公司在 2024 年 10 月的新闻稿中（与其和赛诺菲的合作相关）宣布，其人工智慧驱动的平台已接受1500 万美元的里程碑付款，用于识别符合复杂要求的先导化合物。

同时，皮肤组织晶片平台的商业化进程正在推进，从学术原型发展成为工业化、可扩展的系统。这些微生理装置能够模拟人体皮肤的动态微环境，并因其在评估药物吸收和全身毒性方面的卓越能力，正逐渐成为静态细胞培养的替代方案。目前，各方正投入大量资金以扩大这些技术的生产能力。例如，2024年4月，CN Bio宣布完成2,100万美元的B轮资金筹措，以加速其PhysioMimix系统的商业性化规模化生产，这印证了业界对生理相关毒理学模型的强劲需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球皮肤毒性​​测试市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依测试类型（皮肤刺激性测试、皮肤致敏性测试）
  • 依试验方法（体内试验（动物试验）和体外试验（基于细胞或组织的试验））
  • 按最终用户划分（製药业、化妆品和个人保健产品行业、化学工业、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美皮肤毒性测试市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲皮肤毒性测试市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区皮肤毒性测试市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲皮肤毒性测试市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲皮肤毒性测试市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球皮肤毒性​​测试市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• SGS SA
• Covance, Inc
• Bio-Rad Laboratories Inc.
• Qiagen NV
• GE Healthcare
• Eurofins Scientific Inc
• Merck KgaA
• Thermo Fisher Scientific, Inc.
• Charles River Laboratories International, Inc.
• Catalent, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Dermal Toxicity Testing Market is projected to increase from USD 2.11 Billion in 2025 to USD 3.38 Billion by 2031, expanding at a CAGR of 8.17%. This testing sector is essential for evaluating potential skin damage, such as irritation or corrosion, as well as systemic effects resulting from topical exposure, serving as a cornerstone for safety and compliance within the pharmaceutical, chemical, and cosmetic industries. Growth in this market is largely fueled by strict regulatory mandates like REACH and a rising ethical commitment to substitute animal testing with in vitro and in silico alternatives. Highlighting the scale of substances requiring evaluation, the European Chemical Industry Council (Cefic) reported that the European chemical industry achieved a turnover of €635 billion in 2024.

Despite these growth factors, the market encounters significant obstacles related to the regulatory harmonization and scientific validation of alternative testing methodologies. While non-animal models are progressing, proving their complete equivalence to complex biological systems remains a major difficulty. This challenge potentially hinders the universal acceptance of these methods and restricts the broader expansion of the market, as demonstrating comparable efficacy to traditional models continues to be a substantial hurdle.

Market Driver

The robust growth of the global cosmetics and personal care industry acts as a major catalyst for the dermal toxicity testing market, spurred by the constant release of complex formulations and new ingredients necessitating thorough safety reviews. As consumers become increasingly vigilant about product safety, manufacturers must perform extensive dermal compatibility assessments to ensure compliance with international standards and prevent adverse reactions. This intense product development cycle drives a high demand for toxicological evaluations to ensure market readiness, a scale illustrated by Cosmetics Europe's 'Annual Report 2024', which noted that the European cosmetics and personal care sector achieved retail sales of €104 billion in 2024.

Concurrently, the market is transforming due to the swift uptake of alternative non-animal testing methods, driven by ethical considerations and regulatory updates like the FDA Modernization Act 2.0. This transition has hastened the commercialization of 3D reconstructed human epidermis models, which provide superior predictive accuracy for human skin reactions compared to animal testing. The strategic importance of these innovations is highlighted by Sartorius's agreement in April 2025 to acquire MatTek, a leader in 3D tissue models, for $80 million. Furthermore, the reliance on specialized external expertise supports the contract research sector, evidenced by Charles River Laboratories reporting $600.7 million in revenue for its Discovery and Safety Assessment segment in November 2025.

Market Challenge

A significant barrier facing the Global Dermal Toxicity Testing Market is the complex process of scientifically validating and harmonizing regulations for alternative testing methods. Establishing that non-animal models, such as in silico and in vitro techniques, can fully mimic the intricate physiological responses of complete biological systems is scientifically challenging, causing regulatory bodies to often hesitate in endorsing these new approaches. This caution creates a fragmented regulatory environment where specific tests may be approved in one region but not another, generating considerable uncertainty for service providers and clients navigating diverse compliance standards.

As a result, the absence of harmonization slows the commercial uptake of advanced alternative technologies and limits the market's revenue potential. Manufacturers encounter higher compliance costs and delayed product launches, which effectively stalls the industry's intended shift away from traditional animal-based testing. The economic implications are significant; Cosmetics Europe reported €104 billion in retail sales for the European cosmetics and personal care market in 2024, yet the lack of universally accepted, streamlined validation protocols for assessing this vast volume of products directly impedes the market's operational efficiency and growth trajectory.

Market Trends

The integration of Artificial Intelligence into Predictive Toxicology is transforming the market by shifting safety assessments from reactive, animal-based observations to proactive, data-centric predictions. This trend involves the use of machine learning algorithms to rapidly analyze extensive chemical libraries and forecast toxicity endpoints, encouraging pharmaceutical companies to utilize these platforms for de-risking early-stage assets. The commercial viability of computational toxicology is exemplified by Exscientia, which, according to an October 2024 press release regarding its collaboration with Sanofi, received $15 million in milestone payments after its AI-driven platform successfully identified lead compounds meeting complex requirements.

Simultaneously, the commercialization of Dermal Organ-on-a-Chip platforms is advancing the sector by evolving from academic prototypes to scalable, industrially robust systems. These microphysiological devices mimic the dynamic microenvironment of human skin and are gaining favor over static cell cultures for their superior ability to assess drug absorption and systemic toxicity. Significant investment is being directed toward expanding manufacturing capabilities for these technologies; for instance, CN Bio announced in April 2024 that it raised $21 million in Series B funding specifically to accelerate the commercial scaling of its PhysioMimix systems, underscoring the strong industry push toward physiologically relevant toxicological models.

Key Market Players

• SGS S.A.
• Covance, Inc
• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• GE Healthcare
• Eurofins Scientific Inc
• Merck KgaA
• Thermo Fisher Scientific, Inc.
• Charles River Laboratories International, Inc.
• Catalent, Inc.

Report Scope

In this report, the Global Dermal Toxicity Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermal Toxicity Testing Market, By Test Type

• Skin Irritation Tests
• Skin Sensitization Tests

Dermal Toxicity Testing Market, By Testing Method Type

• In Vivo Testing (Animal-Based Tests)
• In Vitro Testing (Cell-Based or Tissue-Based Tests)

Dermal Toxicity Testing Market, By End User

• Pharmaceuticals industries
• Cosmetics and personal care products industry
• Chemical Industry
• Other

Dermal Toxicity Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermal Toxicity Testing Market.

Available Customizations:

Global Dermal Toxicity Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermal Toxicity Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Skin Irritation Tests, Skin Sensitization Tests)
  • 5.2.2. By Testing Method Type (In Vivo Testing (Animal-Based Tests) and In Vitro Testing (Cell-Based or Tissue-Based Tests))
  • 5.2.3. By End User (Pharmaceuticals industries, Cosmetics and personal care products industry, Chemical Industry, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Dermal Toxicity Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Testing Method Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dermal Toxicity Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Testing Method Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Dermal Toxicity Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Testing Method Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Dermal Toxicity Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Testing Method Type
      • 6.3.3.2.3. By End User

7. Europe Dermal Toxicity Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Testing Method Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dermal Toxicity Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Testing Method Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Dermal Toxicity Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Testing Method Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Dermal Toxicity Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Testing Method Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Dermal Toxicity Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Testing Method Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Dermal Toxicity Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Testing Method Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Dermal Toxicity Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Testing Method Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dermal Toxicity Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Testing Method Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Dermal Toxicity Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Testing Method Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Dermal Toxicity Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Testing Method Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Dermal Toxicity Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Testing Method Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Dermal Toxicity Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Testing Method Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Dermal Toxicity Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Testing Method Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dermal Toxicity Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Testing Method Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Dermal Toxicity Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Testing Method Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Dermal Toxicity Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Testing Method Type
      • 9.3.3.2.3. By End User

10. South America Dermal Toxicity Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Testing Method Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dermal Toxicity Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Testing Method Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Dermal Toxicity Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Testing Method Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Dermal Toxicity Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Testing Method Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dermal Toxicity Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. SGS S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Covance, Inc
• 15.3. Bio-Rad Laboratories Inc.
• 15.4. Qiagen N.V.
• 15.5. GE Healthcare
• 15.6. Eurofins Scientific Inc
• 15.7. Merck KgaA
• 15.8. Thermo Fisher Scientific, Inc.
• 15.9. Charles River Laboratories International, Inc.
• 15.10. Catalent, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer